ARTICLE | Clinical News
Fujifilm-Kyowa JV to develop biosimilar Avastin
October 25, 2012 12:29 AM UTC
Fujifilm Kyowa Kirin Biologics Co. Ltd. announced plans to develop a biosimilar version of cancer drug Avastin bevacizumab. Clinical trials are expected to begin in 2014. Fujifilm Kyowa launched earlier this year as a 50/50 JV between Fujifilm Holdings Corp. (Tokyo:4901) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). The JV already is developing a biosimilar version of autoimmune drug Humira adalimumab, with clinical trials expected to begin in Europe next half. ...